ATAI Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: AtaiBeckley N.V.

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

6 days ago - By: AtaiBeckley N.V.

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

6 days ago - By: AtaiBeckley N.V.

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

20 days ago - By: Benzinga

Analyst Expectations For ATAI Life Sciences's Future

2 months ago - By: Benzinga

Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews

22 days ago - By: atai Life Sciences

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

22 days ago - By: atai Life Sciences

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

22 days ago - By: Zacks Investment Research

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

25 days ago - By: The Motley Fool

Why Atai Life Sciences Stock Was So Lively This Week

26 days ago - By: atai Life Sciences

atai Life Sciences Announces Pricing of Public Offering of Common Shares

26 days ago - By: atai Life Sciences

atai Life Sciences Announces Pricing of Public Offering of Common Shares

a month ago - By: atai Life Sciences

atai Life Sciences Announces Proposed Public Offering of Common Shares

a month ago - By: atai Life Sciences

atai Life Sciences Announces Proposed Public Offering of Common Shares

a month ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

a month ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

2 months ago - By: The Motley Fool

Why Atai Life Sciences Stock Crushed It on Tuesday

2 months ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

2 months ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

2 months ago - By: atai Life Sciences

atai Life Sciences Awarded Grant from the National Institutes of Health

2 months ago - By: atai Life Sciences

atai Life Sciences Awarded Grant from the National Institutes of Health

2 months ago - By: Zacks Investment Research - Mentions: HALO

Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

3 months ago - By: atai Life Sciences

atai Life Sciences to Participate in September Investor Conferences

3 months ago - By: atai Life Sciences

atai Life Sciences to Participate in September Investor Conferences

3 months ago - By: Zacks Investment Research

Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now

3 months ago - By: atai Life Sciences

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

3 months ago - By: atai Life Sciences

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

3 months ago - By: Yahoo Finance

ATAI BECKLEY NV (ATAI) Stock News

ATAI Latest News, Press Relases and Analysis

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

Analyst Expectations For ATAI Life Sciences's Future

Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

Why Atai Life Sciences Stock Was So Lively This Week

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Why Atai Life Sciences Stock Crushed It on Tuesday

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences Awarded Grant from the National Institutes of Health

atai Life Sciences Awarded Grant from the National Institutes of Health

Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

atai Life Sciences to Participate in September Investor Conferences

atai Life Sciences to Participate in September Investor Conferences

Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10